Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer

Breast Cancer Research and Treatment

Volumn 39, Issue 3, 1996, Pages 335-341

  Lønning, Per E ^a   Helle, Svein I ^a   Johannessen, Dag C ^a   Ekse, Dagfinn ^a   Adlercreutz, Herman ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Breast cancer; Disease free interval; Estrogens

Indexed keywords

ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STAGING; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; RELAPSE; REMISSION;

EID: 0029766568     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806162     Document Type: Article

References (23)

1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment, with illustrative cases. Lancet 2: 104-107, 1896
2. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmac Ther 25: 127-205, 1984
3. Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocrine Rev 11: 221-265, 1990
4. Jones AL, Powles TJ, Law M, Tidy A, Easton D, Coombes RC, Smith IE, McKinna JA, Nash A, Ford HT, Gazet JC: Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol 10: 1547-1552, 1992
5. Early Breast Cancer Trialist Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Part 1. Lancet 339: 1-15, 1992
6. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117: 1016-1037, 1992
7. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC: Estrogen replacement therapy in breast cancer survivors. J Am Med Assoc 272: 540-545, 1994
8. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS: A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87: 190-197, 1995
9. Rose C, Theilade K, Boesen E, Salimtschik M, Dombernowsky P, Brünner N, Kjaer M, Mouridsen HT: Treatment of advanced breast cancer with tamoxifen: evaluation of the dose-response relationship at two dose levels. Breast Cancer Res Treat 2: 395-400, 1982
10. Lønning PE, Helle S-I, Johannessen DC, Adlercreutz H, Lien EA, Tally M, Ekse D, Fotsis T, Anker GB, Hall K: Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clin Endocrinol 42: 23-30, 1995
11. Fotsis T, Adlercreutz H: The multicomponent analysis of oestrogens in urine by ion exchange chromatography GC-MS. I. Quantitation of oestrogens after initial hydrolysis of conjugates. J Steroid Biochem 28: 203-213, 1987
12. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hämäläinen E: Estrogen metabolism and excretion in oriental and caucasian women. J Natl Cancer Inst 86: 1076-1082, 1994
13. Lønning PE, Lien EA, Lundgren S, Kvinnsland S: Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22: 327-358, 1992
14. Fracchia AA, Farrow JH, DePalo AJ, Connolly DP, Huvos AG: Castration for primary inoperable or recurrent breast carcinoma. Surg Gyn Obstet 128: 1226-1234, 1969
15. Høst H, Lund E: Age as a prognostic factor in breast cancer. Cancer 57: 2217-2221, 1986
16. Gambrell DR: Proposal to decrease the risk and improve the prognosis in breast cancer. Am J Obstet Gynecol 150: 119-128, 1984
17. Vassilopoulou-Sellin R, Theriault RL: Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. J Natl Cancer Inst Monogr 16: 153-159, 1994
18. Langlands AO, Pocock SJ, Kerr GR, Gore SM: Long-term survival of patients with breast cancer: a study of the curability of the disease. Brit Med J 2: 1247-1251, 1979
19. Eberlein T, Simon R, Fisher S, Lippman ME: Height, weight, and risk of breast cancer relapse. Breast Cancer Res Treat 5: 81-86, 1985
20. Santner SJ, Feil PD, Santen RJ: In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 59: 29-33, 1984
21. Tait GH, Newton CJ, Reed MJ, James VHT: Multiple forms of 17β-hydroxysteroid oxidoreductase in human breast tissue. J Molec Endocr 2: 71-80, 1989
22. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J: Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 79: 3047-3051, 1982
23. De Nosaquo N: Androgens and estrogens in the treatment of disseminated mammary cancer. J Am Med Assoc 172: 1271-1283, 1960